Tonix Pharma (TNXP) just unveiled an announcement.
Tonix Pharmaceuticals Holding Corp. has received Fast Track designation from the FDA for its Tonmya™ product, aimed at managing fibromyalgia, signaling a potential boost for investors tracking healthcare innovations. The Company also intends to seek Priority Review, underscoring its commitment to advancing treatment options for this chronic condition. While this news offers promise, the company cautions that its forward-looking statements carry risks and uncertainties, reminding investors that projections are not guarantees of future performance.
See more insights into TNXP stock on TipRanks’ Stock Analysis page.
